{"nctId":"NCT03979313","briefTitle":"A Study to Evaluate the Safety and Efficacy of MEDI8897 for the Prevention of Medically Attended Lower Respiratory Tract Infection Due to Respiratory Syncytial Virus in Healthy Late Preterm and Term Infants (MELODY)","startDateStruct":{"date":"2019-07-23","type":"ACTUAL"},"conditions":["Respiratory Syncytial Virus Infections"],"count":3012,"armGroups":[{"label":"MEDI8897","type":"EXPERIMENTAL","interventionNames":["Drug: MEDI8897"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"MEDI8897","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Key Inclusion Criteria:\n\n* Healthy infants in their first year of life and born at or after 35 weeks 0 days GA\n* Infants who are entering their first RSV season at the time of screening\n\nKey Exclusion Criteria:\n\n* Meets national or other local criteria to receive commercial palivizumab\n* Any fever (≥ 100.4°F \\[≥ 38.0°C\\], regardless of route) or acute illness within 7 days prior to randomization\n* Active RSV infection (a child with signs/symptoms of respiratory infection must have negative RSV testing) or known prior history of RSV infection\n* Receipt of palivizumab or other RSV monoclonal antibody or any RSV vaccine, including maternal RSV vaccination","healthyVolunteers":true,"sex":"ALL","minimumAge":"0 Years","maximumAge":"1 Year","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"SECONDARY","title":"Number of Participants With MA RSV LRTI With Hospitalisation Through 150 Days Post Dose (Primary Cohort)","description":"Hospitalization Analysed on Primary Cohort Through 150 Days (N=1490 Participants)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"6","spread":null}]},{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"15","spread":null}]},{"measurements":[{"groupId":"OG000","value":"482","spread":null},{"groupId":"OG001","value":"973","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants With MA RSV LRTI Through 150 Days Post Dose (Primary Cohort)","description":"Primary Endpoint Analysed on Primary Cohort Through 150 Days (N=1490 Participants)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"25","spread":null},{"groupId":"OG001","value":"12","spread":null}]},{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"15","spread":null}]},{"measurements":[{"groupId":"OG000","value":"465","spread":null},{"groupId":"OG001","value":"967","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Number of Participants With MA RSV LRTI Through 150 Days Post Dose (All Subjects)","description":"Primary Endpoint Analysed on All Subjects Through 150 Days (N=3012 participants)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"54","spread":null},{"groupId":"OG001","value":"24","spread":null}]},{"measurements":[{"groupId":"OG000","value":"17","spread":null},{"groupId":"OG001","value":"31","spread":null}]},{"measurements":[{"groupId":"OG000","value":"932","spread":null},{"groupId":"OG001","value":"1954","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Number of Participants With MA RSV LRTI With Hospitalisation Through 150 Days Post Dose (All Subjects)","description":"Hospitalization Analysed on All Subjects Through 150 Days (N=3012 participants)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20","spread":null},{"groupId":"OG001","value":"9","spread":null}]},{"measurements":[{"groupId":"OG000","value":"18","spread":null},{"groupId":"OG001","value":"31","spread":null}]},{"measurements":[{"groupId":"OG000","value":"965","spread":null},{"groupId":"OG001","value":"1969","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Number of Participants With Disease From the 2nd RSV Season (All Subjects)","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"19","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]}]},{"type":"SECONDARY","title":"Summary of Serum Concentrations (ug/mL) of MEDI8897 by Group","description":"Number of Subjects with at Least one Assessment","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"89.91","spread":"39.3"},{"groupId":"OG001","value":"164.03","spread":"15.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"74.09","spread":"124.9"},{"groupId":"OG001","value":"105.05","spread":"89.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"68.63","spread":"58.6"},{"groupId":"OG001","value":"100.54","spread":"90.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.32","spread":"63.1"},{"groupId":"OG001","value":"27.73","spread":"62.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.75","spread":"76.7"},{"groupId":"OG001","value":"2.86","spread":"85.7"}]}]}]},{"type":"SECONDARY","title":"Anti-drug Antibody Results by Visit (As Treated Population)","description":"Number of subjects with a positive result and a valid titer result at the specific visit","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"14","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"21","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"81","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":83,"n":997},"commonTop":["Upper respiratory tract infection","Nasopharyngitis","Pyrexia","Dermatitis diaper","Rhinitis"]}}}